徳島大学 教育・研究者情報データベース(EDB)

1. (英) Hori Taiki

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 清水 太郎

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. 安藤 英紀([徳島大学.大学院医歯薬学研究部.薬学域.薬科学部門.生命薬学系.薬物動態制御学])

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. 岡田 直人

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. 山上 紘規([徳島大学.病院.診療科.内科.内分泌・代謝内科])

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. (英) Yasui Saya

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. (英) Hosoki Minae

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. (英) Tojima Akihiro

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. 乙田 敏城

   役割	任意
   貢献度	任意
   学籍番号	推奨

10. 湯浅 智之([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).実践地域診療・医科学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

11. 粟飯原 賢一([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).実践地域診療・医科学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

12. (英) Takishita Makoto

    役割	任意
    貢献度	任意
    学籍番号	推奨

13. 吉田 守美子

    役割	任意
    貢献度	任意
    学籍番号	推奨

14. 安倍 正博

    役割	任意
    貢献度	任意
    学籍番号	推奨

15. 石田 竜弘([徳島大学.大学院医歯薬学研究部.薬学域.薬科学部門.生命薬学系.薬物動態制御学]/[徳島大学.大学院医歯薬学研究部.薬学域.連携研究部門(薬学域).寄附講座系(薬学域).がん細胞と代謝学]/[徳島大学.大学産業院])

    役割	任意
    貢献度	任意
    学籍番号	推奨

16. 中村 信元([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).実践地域診療・医科学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

(英) Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases.

(英) The effects of vaccination are modified by hematological and autoimmune diseases and/or treatment. Anti-SARS-CoV-2 mRNA vaccine contains polyethylene glycol (PEG), it is largely unknown whether PEG influences the effects of vaccination or induces a humoral response. This study examined whether anti-PEG antibodies before vaccination (pre-existing) influenced the acquisition of SARS-CoV-2 antibodies and evaluated the relationship between the development of anti-SARS-CoV-2 antibodies and anti-PEG antibodies after SARS-CoV-2 vaccination in hematological and autoimmune diseases. Anti-SARS-CoV-2 antibody IgG, anti-PEG IgG, and IgM titers were evaluated in patients with hematological and autoimmune diseases after the second dose of BNT162B2. Anti-PEG IgG and IgM titers were also measured before vaccination to examine changes after vaccination and the relationship with vaccine efficacy. In patients with hematological (n = 182) and autoimmune diseases (n = 96), anti-SARS-CoV-2 and anti-PEG antibody titers were evaluated after a median of 33 days from 2nd vaccination. The median anti-SARS-CoV-2 antibody titers were 1901 AU/mL and 3832 AU/mL in patients with hematological and autoimmune disease, respectively. Multiple regression analysis showed that age and days from 2nd vaccination were negatively associated with anti-SARS-CoV-2 antibody titers. Anti-CD20 antibody treatment was negatively correlated with anti-SARS-CoV-2 antibody titers in hematological disease, and C-reactive protein (CRP) was positively correlated with anti-SARS-CoV-2 antibody titers in autoimmune disease. Baseline anti-PEG antibody titers were significantly higher in patients with autoimmune disease but were not correlated with anti-SARS-CoV-2 antibody titers. Patients with increased anti-PEG IgG acquired higher anti-SARS-CoV-2 antibody titers in patients with autoimmune disease. Anti-SARS-CoV-2 antibody acquisition was suboptimal in patients with hematological disease, but both anti-SARS-CoV-2 antibody and anti-PEG IgG were acquired in patients with autoimmune disease, reflecting robust humoral immune response. Pre-existing anti-PEG antibody titers did not affect anti-SARS-CoV-2 antibody acquisition.

1. (英) PublicationType: Journal Article